GUTS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's clinical sites compromised the integrity of its efficacy results; (ii) accordingly, Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On January 29, 2026, Fractyl issued a press release announcing six-month data from the REMAIN-1 Midpoint Cohort, disclosing that "Revita-treated patients experienced a 4.5% weight regain vs 7.5% in the sham arm at 6 months" and that "[t]he Midpoint Cohort was not designed to be sufficiently powered for efficacy analysis," and hosted a conference call during which CEO Rajagopalan indicated that issues at one of the study sites "had higher-than-expected regain across both arms." On this news, Fractyl's stock price fell $1.245, or 68.03%, to close at $0.585 per share on January 29, 2026.

On January 30, 2026, following the release of post-market Canaccord Genuity and Morgan Stanley reports, with Morgan Stanley downgrading the Company to "Equal-weight" from "Overweight" and cutting its price target to $2.00 from $8.00, characterizing the results as "[d]isappoint[ing]." On this news, Fractyl's stock price fell $0.125, or 21.37%, to close at $0.46 per share on January 30, 2026.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Fractyl's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.